Welcome to KaMoZo’s universe!
Welcome to a world of limitless possibilities, where the journey is as exhilarating as the destination, and where every moment is an opportunity to make your mark.
Our mission is to challenge the status quo, embrace innovation, and create meaningful, lasting impact through everything we do.
Hello World!
February 8, 2025
KaMoZo Biologics, LLC is formed! We were registered by the Tennessee Secretary of State in Davidson County (Nashville) on February 4, 2025.
Congratulations!
February 24, 2025
Congratulations to Madeline Serbent, KaMoZo’s Co-Founder, COO, & CMO on acquiring a Ph.D. degree in Chemical Engineering from the Vanderbilt University School of Engineering.
On February 20, 2025, Maddie finished a Ph.D. program in the Department of Chemical and Biomolecular Engineering by successfully defending her dissertation entitled “Direct observation of bidirectional motility by the cellobiohydrolase TfCel6B.”
KaMoZo’s first therapeutics are ready for in vitro testing!
May 15, 2025
KaMoZo is currently in negotiations with five CRO service laboratories for in vitro testing of our first line of investigational compounds: KMZ-HN-01010, KMZ-HN-01070, KMZ-HN-01090, KMZ-HN-02010, KMZ-HN-02070, and KMZ-HN-02090. These compounds are being developed as intracellular anti-cancer therapeutics.
Our goal is to evaluate their efficacy in cell models of triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC). The planned testing will encompass assessments of cytotoxicity and EC50 values, as well as their effects on cancer cell growth rate, viability, and induction of apoptosis.
Furthermore, we intend to analyze the compounds’ capacity to suppress the production of cancer-specific cytokines and chemokines, such as TNFα, IL-1, IL-6, IL-17, CCL2, CXCL1, CXCL8, and CXCL12.
Finally, we will examine protein levels in nuclear fractions to determine their ability to inhibit the nuclear import of oncogenic transcription factors, including NF-κB, STAT3, HIFs, Myc, NFIB, RUNX2, and Sp1.
June 11, 2025
Ichor Life Sciences, Inc., has been selected to analyze activity of our therapeutics in viability/proliferation/apoptosis assays using cell lines of cancer models including ovarian serous cystadenocarcinoma, malignant melanoma, and non-small cell lung cancer.
February 12, 2026
KaMoZo Biologics converts to Delaware corporation company!
February, 20, 2026
KaMoZo welcomes new member, John Wesley Wilson, Esq. Wesley is an alumnus of University of Oxford (BA) and Columbia University Law School (JD). He will serve as company’s President and General Counsel.